PRENATAL EXPOSURE TO MODAFINIL ALTERS LOCOMOTOR BEHAVIOUR AND LEUCOCYTE PHAGOCYTOSIS IN MICE

Varování

Publikace nespadá pod Filozofickou fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Název česky Prenatální expozice modafinilu ovlivňuje lokomoci a leukocytární fagocytózu u myších samců
Autoři

RUDÁ Jana AMCHOVÁ Petra MÁCHALOVÁ Alena PISTOVČÁKOVÁ Jana ŠULCOVÁ Alexandra

Rok publikování 2018
Druh Článek v odborném periodiku
Časopis / Zdroj Psychiatria danubina
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.24869/psyd.2018.356
Klíčová slova modafinil; prenatal administration; locomotion; phagocytosis; mice
Popis Background: Modafinil is a psychostimulant drug prescribed mainly for treatment of narcolepsy but is used as a "smart drug" by wide populations to increase wakefulness, concentration and overall mental performance. The aim of this study was to assess potential developmental toxicity of modafinil. Materials and methods: Pregnant female mice were given either saline or modafinil (50 mg/kg orally) from gestational day (GD) 3 to GD 10 and then a challenge dose on the GD 17. The male offspring were treated analogously at the age of 10 weeks. Changes in the spontaneous locomotor/exploratory behaviour and anxiogenic profile in the open-field test were assessed in naive animals, after an acute and 8th modafinil dose and the challenge dose following a 7-day wash-out period. One month after completion of the behavioural study, the leukocyte phagocytosis was examined by zymosan induced and luminol-aided chemiluminiscence assay in vitro. Results: The most important finding of this study was the immunosuppressing effect on leukocyte activity, hypolocomotion and increased behavioural response to modafinil-induced psychostimulation caused by prenatal exposure to the same drug. We did not detect significantly altered anxiety-related behaviour in any group disregarding the pre- and postnatal treatments. Conclusion: This is the first evidence of developmental toxicity of modafinil which needs to be taken into account as a potential risk factor when modafinil is administered to women who may become or are pregnant.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.